Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S

Reuters

06 Jun

Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S

DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. $(AYTU)$ announced that it has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA™ (gepirone) extended-release tablets in the United States. EXXUA, a novel antidepressant, is the first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for treating major depressive disorder (MDD) in adults. The transaction is financed by long-term, healthcare-focused institutional investors, including Nantahala Capital Management and Stonepine Capital Management. Aytu is preparing to launch EXXUA in the U.S. by the fourth quarter of 2025, aiming to make it a central element of their commercial strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1036228) on June 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2541852460"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541852460\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2541852460?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-06 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541852460","market":"us","top_or_hot":-1,"title":"Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        DENVER, CO / ACCESS Newswire / June 6, 2025 / <a href=\"https://laohu8.com/S/AYTUZ\">Aytu BioPharma, Inc.</a> <a href=\"https://laohu8.com/S/AYTU\">$(AYTU)$</a> announced that it has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA™ (gepirone) extended-release tablets in the United States. EXXUA, a novel antidepressant, is the first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for treating major depressive disorder (MDD) in adults. The transaction is financed by long-term, healthcare-focused institutional investors, including Nantahala Capital Management and Stonepine Capital Management. Aytu is preparing to launch EXXUA in the U.S. by the fourth quarter of 2025, aiming to make it a central element of their commercial strategy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1036228) on June 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-06 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        DENVER, CO / ACCESS Newswire / June 6, 2025 / <a href=\"https://laohu8.com/S/AYTUZ\">Aytu BioPharma, Inc.</a> <a href=\"https://laohu8.com/S/AYTU\">$(AYTU)$</a> announced that it has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA™ (gepirone) extended-release tablets in the United States. EXXUA, a novel antidepressant, is the first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for treating major depressive disorder (MDD) in adults. The transaction is financed by long-term, healthcare-focused institutional investors, including Nantahala Capital Management and Stonepine Capital Management. Aytu is preparing to launch EXXUA in the U.S. by the fourth quarter of 2025, aiming to make it a central element of their commercial strategy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1036228) on June 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL5Lzyrd:1","article_id":"2541852460","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541852460","pubTimestamp":1749211242,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc.  announced that it has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA  extended-release tablets in the United States. EXXUA, a novel antidepressant, is the first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for treating major depressive disorder  in adults. The transaction is financed by long-term, healthcare-focused institutional investors, including Nantahala Capital Management and Stonepine Capital Management. Aytu is preparing to launch EXXUA in the U.S. by the fourth quarter of 2025, aiming to make it a central element of their commercial strategy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","AYTU":"Aytu BioScience, Inc."},"translate_title":"Aytu BioPharma Inc.获得EXXUA在美国商业化用于MDD治疗的独家协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AYTU":0.9},"content_text":"Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S\n    \n\n        DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. $(AYTU)$ announced that it has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA™ (gepirone) extended-release tablets in the United States. EXXUA, a novel antidepressant, is the first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for treating major depressive disorder (MDD) in adults. The transaction is financed by long-term, healthcare-focused institutional investors, including Nantahala Capital Management and Stonepine Capital Management. Aytu is preparing to launch EXXUA in the U.S. by the fourth quarter of 2025, aiming to make it a central element of their commercial strategy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1036228) on June 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}